loader
Please Wait
Applying Filters...

Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 15174 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Fermion Oy

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    Key Products KEY PRODUCTS

    INTERMEDIATES

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    PharmaCompass Sponsored Ads

    Temad- We think of world-class quality.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Fermion Oy (1)

    filter

    01 GLIPIZIDE (1)

    filter

    01 Finland (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    FERMION OY

    Contact Supplier
    • FDA
    • EDQM
    Virtual BoothWith Fermion, start the journey of your innovative API.
    Contact Supplier Contact Supplier
    Flag Finland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GLIPIZIDE

    PDF Supplier PDF
    URL Supplier Web Content
    15174
    Active
    2000-12-04
    Complete
    2020-06-12
    2020-06-05
    II
    fermion

    CPhI North America

    Booth #1117

    envelop Contact Supplier

    Looking for Drug Master Files (DMF) for 15174 of Fermion Oy

    Looking for Drug Master Files (DMF) for 15174 of Fermion Oy 1

    20

    Fermion Oy, based in Finland, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

    They are recognized for With Fermion, start the journey of your innovative API.

    One of their notable products is GLIPIZIDE, with a corresponding US DMF Number 15174.

    Remarkably, this DMF maintains an Active status since its submission on December 04, 2000, highlighting commitment to regulatory compliance.

    Their GDUFA DMF Review was successfully complete, with a review date of June 12, 2020, and payment made on June 05, 2020, indicating their dedication to facilitating drug approvals, Categorized as Type II

    Post Enquiry
    POST ENQUIRY